Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016 Mar 16, 2017
Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders Mar 14, 2017
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101 Feb 28, 2017
Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing Feb 02, 2017
Fortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis Jan 04, 2017
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol Jan 03, 2017
Fortress Biotech Announces Publication on MB‐101 (IL13Rα2‐specific CAR T cells) for the Treatment of Glioblastoma in New England Journal of Medicine Dec 28, 2016
Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology Nov 21, 2016
